rs1057520109
Variant summary
Our verdict is Likely pathogenic. Variant got 9 ACMG points: 9P and 0B. PM2_SupportingPP2PP3PP4PS1PM5_Supporting
This summary comes from the ClinGen Evidence Repository: The c.171G>T variant in the glucokinase gene, GCK, causes an amino acid change of methionine to isoleucine at codon 57 (p.(Met57Ile)) of NM_000162.5. This variant is absent from gnomAD v2.1.1 and v4.1 (PM2_Supporting). GCK is defined by the ClinGen MDEP as a gene that has a low rate of benign missense variation and has pathogenic missense variants as a common mechanism of disease (PP2). This variant is predicted to be deleterious by computational evidence, with a REVEL score of 0.987, which is greater than the MDEP VCEP threshold of 0.70 (PP3). This variant was identified in an individual with a clinical history highly specific for GCK-MODY (FBG 5.5-8 mmol/L and HbA1c 5.6 - 7.6%) (PP4; PMID:34440516). The nucleotide change c.171G>A, which results in the same amino acid change, has been classified as pathogenic for GCK-hyperglycemia by the ClinGen MDEP (PS1). Another missense variant at the same codon, c.170T>G (p.Met57Arg), has been classified as likely pathogenic by the ClinGen MDEP (PM5_Supporting). In summary, c.171G>T p.(Met57Ile) meets the criteria to be classified as likely pathogenic for monogenic diabetes. ACMG/AMP criteria applied, as specified by the ClinGen MDEP (specification version 1.3.0, approved 8/11/2023): PM2_Supporting, PM5_Supporting, PP2, PP3, PP4, PS1). LINK:https://erepo.genome.network/evrepo/ui/classification/CA16603236/MONDO:0015967/086
Frequency
Consequence
NM_000162.5 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_pathogenic. Variant got 9 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
GCK | NM_000162.5 | c.171G>T | p.Met57Ile | missense_variant | Exon 2 of 10 | ENST00000403799.8 | NP_000153.1 | |
GCK | NM_033507.3 | c.174G>T | p.Met58Ile | missense_variant | Exon 2 of 10 | NP_277042.1 | ||
GCK | NM_033508.3 | c.168G>T | p.Met56Ile | missense_variant | Exon 3 of 11 | NP_277043.1 | ||
GCK | NM_001354800.1 | c.171G>T | p.Met57Ile | missense_variant | Exon 2 of 11 | NP_001341729.1 |
Ensembl
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome Cov.: 34
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Monogenic diabetes Pathogenic:1
The c.171G>T variant in the glucokinase gene, GCK, causes an amino acid change of methionine to isoleucine at codon 57 (p.(Met57Ile)) of NM_000162.5. This variant is absent from gnomAD v2.1.1 and v4.1 (PM2_Supporting). GCK is defined by the ClinGen MDEP as a gene that has a low rate of benign missense variation and has pathogenic missense variants as a common mechanism of disease (PP2). This variant is predicted to be deleterious by computational evidence, with a REVEL score of 0.987, which is greater than the MDEP VCEP threshold of 0.70 (PP3). This variant was identified in an individual with a clinical history highly specific for GCK-MODY (FBG 5.5-8 mmol/L and HbA1c 5.6 - 7.6%) (PP4; PMID: 34440516). The nucleotide change c.171G>A, which results in the same amino acid change, has been classified as pathogenic for GCK-hyperglycemia by the ClinGen MDEP (PS1). Another missense variant at the same codon, c.170T>G (p.Met57Arg), has been classified as likely pathogenic by the ClinGen MDEP (PM5_Supporting). In summary, c.171G>T p.(Met57Ile) meets the criteria to be classified as likely pathogenic for monogenic diabetes. ACMG/AMP criteria applied, as specified by the ClinGen MDEP (specification version 1.3.0, approved 8/11/2023): PM2_Supporting, PM5_Supporting, PP2, PP3, PP4, PS1). -
not provided Pathogenic:1
- -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at